Development of acoustically isolated extracellular plasma vesicles for biomarker discovery in allogeneic hematopoietic stem cell transplantation

Table 1 Patients characteristics

	Age/gender (m/f)	Disease/− stage	Stem cell source, HLA matching	Donor type/age/ gender	Conditioning regimen	CMV, EBV status (R/D)
Pat 1	51/m	MM/relapse after autologous Tx	PB, 11/12	MUD/22/ m	Flu/Tre/ATG	+/−, +/+
Pat 2	37/m	Sezary’s syndrome	PB, full	MRD/47/m	Cy/TBI	+/−, +/+
Pat 3	35/f	hrAML	PB, full	MUD/20/f	Flu/Bu4/ATG	+/+, +, n.d.
Pat 4	46/m	hrAML	PB, 8/8	MUD/29/f	Flu/Bu4/ATG	+/−, +/+
Pat 5	21/m	preB-ALL, CR2	PB, 7/8	MUD/43/m	Cy/TBI/ATG	+/−, +/+
Pat 6	63/m	MDS, RAEB 1	PB, full	MRD/59/m	FluTre	−/−, +/+
Pat 7	68/m	AML, IR	PB, 8/8	MUD/34/m	Flu/Bu2/ATG	+/+, −/n.d.
Pat 8	59/f	Post-ET myelofibrosis	PB, 11/12	MUD/23/m	Flu/Bu3/ATG	+/+, +/+
Pat 9	27/f	hrMDS	PB, full	MUD/38/m	Flu/Tre/ATG	+/−, +, n.d.
Pat 10	69/m	MDS/AML	PB, 10/12	MUD/37/m	FluBu2ATG	+/−, +/+
Pat 11	64/m	MDS/AML	PB, 10/12	MUD/26/f	Flu/Tre/ATG	+/−, +/n.d.
Pat 12	71/m	hrMDS	PB, 10/12	MUD/35/m	Flu/Tre/ATG	+/−, +/n.d.
Pat 13	60/m	MDS/AML	PB, full	MRD/57/m	FluTre	−/−, +/+
Pat 14	67/f	Post-ET myelofibrosis	PB, 10/12	MUD/30/f	Flu/Bu3/ATG	−/+, +/+
Pat 15	64/f	hrAML	PB, 11/12	MUD/20/f	Flu/Bu3/ATG	+/+, +/+
Pat 16	66/m	MCL, relapse after autologous Tx	PB, 10/12	MUD/34/m	Flu/Cy/TBI/ATG	+/−, +/n.d.
Pat 17	42/m	MDS/AML	PB, full	MRD/56/f	FluTre	+/+, +/+
Pat 18	21/f	AML, CR2	PB, full	MRD/19/m	Flu/Bu4	+/+, n.d./n.d.
Pat 19	67/m	hrAML	PB, 11/12	MUD/24/m	Flu/Bu2/ATG	+/−, +/n.d.
Pat 20	30/m	hrT-ALL	PB/ full	MRD/33/m	Cy/TBI	+/+, +/+

Abbreviations: m male, f female, HLA human leukocyte antigen, MUD matched unrelated donor, MRD matched related donor, CMV cytomegalovirus, EBV Ebstein Barr virus, D donor, R recipient, PB peripheral blood stem cells, Tx transplantation, n.d. not determined, hrAML high-risk acute myeloid leukemia, preB-ALL acute pre-B lymphoblastic leukemia, MDS myelodysplastic syndrome, RAEB1 refractory anemia with excess blasts 1, IR intermediate risk, CR2 second complete remission, ET essential thrombocytosis, hrT-ALL high-risk acute T-lymphoblastic leukemia, MCL mantle cell lymphoma
Conditioning regimens: Cy/TBI: cyclophosphamide 120 mg/kg, fractionated total body irradiation12 Gy Cy/TBI/ATG: cyclophosphamide 120 mg/kg, fractionated total body irradiation 12 Gy, antithymocyte globulin 6 mg/kg
Flu/Cy/TBI/ATG: fludarabine 180 mg/m², cyclophosphamide 60 mg/kg, fractionated total body irradiation 6 Gy, antithymocyte globulin 6 mg/kg
Flu/Tre: fludarabine 150 mg/m², treosulfan 2.8 g/m² Flu/Tre/ATG: fludarabine 150 mg/m², treosulfan 2.8 g/m², antithymocyte globulin 4 mg/kg Flu/Bu2, (3), (4)/ATG: fludarabine 150 mg/m², busulfan 6.4 mg/kg, (9.6 mg/kg), (12.8 mg/kg); antithymocyte globulin 4 mg/kg

ISSN: 2050-7771